{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T02:27:31Z","timestamp":1773973651602,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Injection of Botulinum neurotoxin (BoNT) is regarded as standard treatment for spasmodic dysphonia (SD), reducing the overactivity of the affected muscles. Due to the lack of standardized outcome parameters for diagnosing SD or assessing its treatment over time, the evaluation of systematic clinical evidence on the effects of BoNT therapy on SD symptom control is difficult. The registry presented in this article aimed to evaluate outcomes after BoNT treatment in SD patients in Austria and Germany, based on selected subjective and objective voice parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>41 patients with SD were included in this multicentric registry, after drop-out of 2 patients the results of 39\/41 (95.1%) patients could be analyzed per protocol. Demographic and treatment characteristics as well as the occurrence of therapy-related side effects were recorded. Perceptual voice sound evaluation (RBH scale), voice range profile measurements (VRP), number of spasms, and severity of voice strain were assessed. Patients were asked to complete the Voice Handicap Index (VHI-9i), the Communicative Participation Item Bank (CPIB), and indicate their perceived phonation effort on a VAS scale. The parameters were compared between baseline and 1-month post-BoNT treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The patients received all BoNT type A (Xeomin\n                      <jats:sup>\u00ae<\/jats:sup>\n                      \/Merz, Allergan\n                      <jats:sup>\u00ae<\/jats:sup>\n                      \/Allergan or Dysport\n                      <jats:sup>\u00ae<\/jats:sup>\n                      \/Ipsen). SD symptoms did not affect the frequency or dynamic range of the singing voice nor did they affect MPT; in contrast all the other parameters assessed were aberrant at baseline. BoNT treatment improved Jitter-%, Dysphonia Severity Index (DSI), degrees of roughness and hoarseness, but failed to restore them to normal. BoNT significantly reduced the voice spasm and strain. Phonation effort improved by approximately 50%. VHI-9i classification was reduced from moderate to mild after treatment, and CPIB from moderate to mild. The VHI-9i results were significantly positively correlated with the CPIB results.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results of this registry showed that BoNT injection, the current off-label treatment of SD symptoms, failed to restore normal voice quality. This registry\u2019s outcomes also indicate that the choice of the applied BoNT brand is site-specific and does not appear to be associated with differences in efficacy. We also showed that the effects of the BoNT on the SD symptoms are best described by semi-quantitative outcome measures such as spasm counts and voice strain, and by patients-reported outcome measures (PROMs), such as CPIB and VHI-9i than by more objective parameters such as frequency and dynamic range of the singing voice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00405-025-09995-5","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T19:53:25Z","timestamp":1769975605000},"page":"1847-1855","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessing the effects of botulinum toxin therapy for spasmodic dysphonia: An Austria-Germany registry"],"prefix":"10.1007","volume":"283","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9978-6474","authenticated-orcid":false,"given":"Berit","family":"Schneider-Stickler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd Fabian","family":"Volk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Galvan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annabella","family":"Kurz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Leonhard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadeus","family":"Nawka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,1]]},"reference":[{"key":"9995_CR1","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1097\/00005537-199810000-00003","volume":"108","author":"A Blitzer","year":"1998","unstructured":"Blitzer A, Brin MF, Stewart CF (1998) Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope 108:1435\u20131441","journal-title":"Laryngoscope"},{"key":"9995_CR2","unstructured":"Center NI of, HTG, Spasmodic RDI (2021) dysphonia. https:\/\/rarediseases.info.nih.gov\/diseases\/7668\/spasmodic-dysphonia"},{"key":"9995_CR3","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1177\/0194599817728521","volume":"157","author":"JM Hintze","year":"2017","unstructured":"Hintze JM, Ludlow CL, Bansberg SF, Adler CH, Lott DG (2017) Spasmodic dysphonia: a review. Part 1: pathogenic factors. Otolaryngol Head Neck Surg 157:551\u2013557","journal-title":"Otolaryngol Head Neck Surg"},{"key":"9995_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.anl.2014.08.012","volume":"42","author":"I Tateya","year":"2015","unstructured":"Tateya I, Omori K, Kojima H, Naito Y, Hirano S, Yamashita M et al (2015) Type II thyroplasty changes cortical activation in patients with spasmodic dysphonia. Auris Nasus Larynx 42:139\u201344","journal-title":"Auris Nasus Larynx"},{"key":"9995_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1177\/000348941112000708","volume":"120","author":"K Tanner","year":"2011","unstructured":"Tanner K, Roy N, Merrill RM, Sauder C, Houtz DR, Smith ME (2011) Spasmodic dysphonia: onset, course, socioemotional effects, and treatment response. Ann Otol Rhinol Laryngol 120:465\u201373","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"9995_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/lary.26655","volume":"128","author":"N Mor","year":"2018","unstructured":"Mor N, Simonyan K, Blitzer A (2018) Central voice production and pathophysiology of spasmodic dysphonia. Laryngoscope 128:177\u2013183","journal-title":"Laryngoscope"},{"key":"9995_CR7","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.otohns.2005.09.008","volume":"133","author":"A Blitzer","year":"2005","unstructured":"Blitzer A (2005) Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia. Otolaryngol Head Neck Surg 133:836\u2013838","journal-title":"Otolaryngol Head Neck Surg"},{"key":"9995_CR8","first-page":"519","volume":"29","author":"TC Flynn","year":"2003","unstructured":"Flynn TC, Clark E 2 (2003) Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion. Dermatol Surg 29:519\u2013522 discussion 522","journal-title":"Dermatol Surg"},{"key":"9995_CR9","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1002\/lary.21966","volume":"121","author":"SL Fulmer","year":"2011","unstructured":"Fulmer SL, Merati AL, Blumin JH (2011) Efficacy of laryngeal botulinum toxin injection: comparison of two techniques. Laryngoscope 121:1924\u20131928","journal-title":"Laryngoscope"},{"key":"9995_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/327928","volume":"2014","author":"JW Kim","year":"2014","unstructured":"Kim JW, Park JH, Park KN, Lee SW (2014) Treatment efficacy of electromyography versus fiberscopy-guided botulinum toxin injection in adductor spasmodic dysphonia patients: a prospective comparative study. Sci World J 2014:327928","journal-title":"Sci World J"},{"key":"9995_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0892-1997(02)00080-2","volume":"16","author":"S Bielamowicz","year":"2002","unstructured":"Bielamowicz S, Stager SV, Badillo A, Godlewski A (2002) Unilateral versus bilateral injections of botulinum toxin in patients with adductor spasmodic dysphonia. J Voice 16:117\u2013123","journal-title":"J Voice"},{"key":"9995_CR12","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jvoice.2014.08.011","volume":"29","author":"DE Rosow","year":"2015","unstructured":"Rosow DE, Pechman A, Saint-Victor S, Lo K, Lundy DS, Casiano RR (2015) Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients. J Voice 29:352\u2013355","journal-title":"J Voice"},{"key":"9995_CR13","first-page":"622","volume":"39","author":"A Eskander","year":"2010","unstructured":"Eskander A, Fung K, McBride S, Hogikyan N (2010) Current practices in the management of adductor spasmodic dysphonia. J Otolaryngol Head Neck Surg 39:622\u2013630","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"9995_CR14","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1177\/000348940111000503","volume":"110","author":"S Bielamowicz","year":"2001","unstructured":"Bielamowicz S, Squire S, Bidus K, Ludlow CL (2001) Assessment of posterior cricoarytenoid botulinum toxin injections in patients with abductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 110:406\u2013412","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"9995_CR15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jvoice.2009.08.003","volume":"25","author":"KA Kendall","year":"2011","unstructured":"Kendall KA, Leonard RJ (2011) Interarytenoid muscle botox injection for treatment of adductor spasmodic dysphonia with vocal tremor. J Voice 25:114\u2013119","journal-title":"J Voice"},{"key":"9995_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jvoice.2021.07.026","volume":"38","author":"W Ryan","year":"2022","unstructured":"Ryan W, Alnouri G, Sataloff RT (2022) Neurectomy and myomectomy for treatment of spasmodic dysphonia. J Voice 38:239\u2013242","journal-title":"J Voice"},{"issue":"1","key":"9995_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jvoice.2021.07.003","volume":"38","author":"N Kodama","year":"2024","unstructured":"Kodama N, Sanuki T, Miyamoto T, Tashiro J (2024) Effects and differences of voice therapy on spasmodic dysphonia and muscle tension dysphonia: a retrospective pilot study. J Voice 38(1):129\u2013135","journal-title":"J Voice"},{"key":"9995_CR18","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.anl.2021.10.011","volume":"49","author":"T Sanuki","year":"2022","unstructured":"Sanuki T, Nishimura T, Aburada T, Fukushima M (2022) Titanium bridge modification for type 2 thyroplasty to improve device mechanical & safety performance. Auris Nasus Larynx 49:460\u2013467","journal-title":"Auris Nasus Larynx"},{"issue":"5","key":"9995_CR19","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1007\/s00405-024-08480-9","volume":"281","author":"A Ricci-Maccarini","year":"2024","unstructured":"Ricci-Maccarini A, Mozzanica F, Fantini M, Dadduzio S, Bergamini G, Fustos R, Schindler A (2024) Validity, reliability and reproducibility of the VLS parameters form for the collection of videolaryngostroboscopic basic findings. Eur Arch Otorhinolaryngol 281(5):2489\u20132497","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"9995_CR20","unstructured":"Seidner W, Nawka T, Anders LC, B\u00fcttner M, Fuchs M, Schr\u00f6ter-Morasch H et al (2014) Aids to voice diagnostics. XION GmbH"},{"key":"9995_CR21","doi-asserted-by":"publisher","unstructured":"Schneider-Stickler B, Bigenzahn W (2013) Stimmdiagnostik. Springer Vienna. 2nd edition.\u00a0https:\/\/doi.org\/10.1007\/978-3-7091-1480-3","DOI":"10.1007\/978-3-7091-1480-3"},{"key":"9995_CR22","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.3390\/jcm10153325","volume":"10","author":"F Caffier","year":"2021","unstructured":"Caffier F, Nawka T, Neumann K, Seipelt M, Caffier PP (2021) Validation and classification of the 9-Item voice handicap index (VHI-9i). J Clin Med 10:3325","journal-title":"J Clin Med"},{"key":"9995_CR23","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/lary.28897","volume":"131","author":"Y Yiu","year":"2021","unstructured":"Yiu Y, Baylor CR, Bamer AM, Shelly S, Klein AM, Garrett CG et al (2021) Validation of the communicative participation item bank as an outcome measure for spasmodic dysphonia. Laryngoscope 131:859\u201364","journal-title":"Laryngoscope"},{"key":"9995_CR24","first-page":"2077","volume":"89","author":"S Srirompotong","year":"2006","unstructured":"Srirompotong S, Saeseow P, Taweesaengsuksakul R, Kharmwan S, Srirompotong S (2006) Botulinum toxin injection for treatment of spasmodic dysphonia: experience at Srinagarind hospital. J Med Assoc Thai 89:2077\u20132080","journal-title":"J Med Assoc Thai"},{"key":"9995_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jvoice.2016.01.006","volume":"31","author":"AW Namin","year":"2017","unstructured":"Namin AW, Christopher KM, Eisenbeis JF (2017) Botulinum toxin dosing trends in spasmodic dysphonia over a 20-year period. J Voice 31:107\u2013110","journal-title":"J Voice"},{"key":"9995_CR26","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/archotol.127.4.393","volume":"127","author":"RP Mehta","year":"2001","unstructured":"Mehta RP, Goldman SN, Orloff LA (2001) Long-term therapy for spasmodic dysphonia: acoustic and aerodynamic outcomes. Arch Otolaryngol Head Neck Surg 127:393\u2013399","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"9995_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jvoice.2013.05.008","volume":"28","author":"DM Orbelo","year":"2014","unstructured":"Orbelo DM, Duffy JR, Borst BJH, Ekbom D, Maragos NE (2014) Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor. J Voice 28:123\u2013127","journal-title":"J Voice"},{"key":"9995_CR28","volume":"49","author":"G French","year":"2020","unstructured":"French G, Bosch JD, Randall DR (2020) Retrospective review of dosing trends in botulinum toxin injections for the treatment of adductor spasmodic dysphonia in a long-term cohort. J Otolaryngol 49:4","journal-title":"J Otolaryngol"},{"key":"9995_CR29","doi-asserted-by":"publisher","first-page":"715","DOI":"10.54029\/2021cwp","volume":"26","author":"T Nguyen","year":"2021","unstructured":"Nguyen T, Tran N, Nguyen T, Nguyen T (2021) Botulinum toxin treatment for adductor spasmodic dysphonia with EMG and endoscopic guidance. Neurol Asia 26:715\u2013719","journal-title":"Neurol Asia"},{"key":"9995_CR30","doi-asserted-by":"publisher","first-page":"540e13","DOI":"10.1016\/j.jvoice.2021.10.001","volume":"38","author":"A Rumbach","year":"2022","unstructured":"Rumbach A, Aiken P, Novakovic D (2022) Treatment outcome measures for spasmodic dysphonia: a systematic review. J Voice 38:540e13-540e43","journal-title":"J Voice"},{"key":"9995_CR31","first-page":"1","volume":"37","author":"EW Reid","year":"2022","unstructured":"Reid EW, Nobriga CV (2022) Spasmodic dysphonia: introductory phonetic analyses. Clin Linguist Phon 37:1\u201316","journal-title":"Clin Linguist Phon"},{"key":"9995_CR32","doi-asserted-by":"publisher","first-page":"667e1","DOI":"10.1016\/j.jvoice.2011.08.011","volume":"26","author":"LJ White","year":"2012","unstructured":"White LJ, Hapner ER, Klein AM, Delgaudio JM, Hanfelt JJ, Jinnah HA et al (2012) Coprevalence of anxiety and depression with spasmodic dysphonia: a case-control study. J Voice 26:667e1\u2013667e6","journal-title":"J Voice"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-025-09995-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-025-09995-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-025-09995-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:52:03Z","timestamp":1773971523000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-025-09995-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["9995"],"URL":"https:\/\/doi.org\/10.1007\/s00405-025-09995-5","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,1]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}